Lexicon Pharmaceuticals/ US5288723027 /
| 2024-07-26 9:59:55 PM | Chg. +0.04 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 2.38USD | +1.71% | 79,168 Turnover: 188,742.02 |
-Bid Size: - | -Ask Size: - | 2.43 | 2.32 |
GlobeNewswire
06-19
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Re...
GlobeNewswire
06-18
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Re...
GlobeNewswire
06-14
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored...
GlobeNewswire
05-29
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
GlobeNewswire
05-14
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Hear...
GlobeNewswire
05-09
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
GlobeNewswire
05-02
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
04-29
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
GlobeNewswire
04-29
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on ...
GlobeNewswire
04-03
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire
03-25
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Spon...
GlobeNewswire
03-12
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotaglif...
GlobeNewswire
03-11
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
03-11
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
GlobeNewswire
03-11
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
GlobeNewswire
2023-12-21
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
GlobeNewswire
2023-11-30
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathi...
GlobeNewswire
2023-11-22
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and th...
GlobeNewswire
2023-11-12
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclero...
GlobeNewswire
2023-11-11
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American...
GlobeNewswire
2023-11-10
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
GlobeNewswire
2023-11-08
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
